Ritter Pharmaceuticals to Host Expert Call with Dr. William Chey on February 20, 2019
February 12 2019 - 8:30AM
Leading Gastrointestinal Disease Expert to
Address Unmet Medical Need in Lactose Intolerance and the Potential
of Phase 3 Drug Candidate RP-G28
Ritter Pharmaceuticals, Inc. (Nasdaq: RTTR) (“Ritter
Pharmaceuticals” or the “Company”), a developer of innovative
therapeutic products that modulate the gut microbiome to treat
gastrointestinal diseases with an initial focus on the development
of RP-G28, a drug candidate with the potential to be the first
FDA-approved treatment for lactose intolerance (LI), today
announced that Dr. William Chey, Professor of Medicine, Director of
the GI Physiology Laboratory, and Co-Director of the Michigan Bowel
Control Program at the University of Michigan will be the subject
of an expert call to be held on February 20, 2019 at 1:00 PM
ET/10:00 AM PT.
The call can be accessed via the following link:
https://slingshotinsights.com/projects/965
Dr. Chey will be discussing:
- The unmet medical need and target population for a potential
pharmaceutical grade treatment of lactose intolerance (LI)
- How LI is diagnosed in practice, the shortcomings of current
treatment options and the role the microbiome plays in LI and the
mechanism of action of RP-G28.
- Insights regarding the ongoing, phase 3 clinical trial of
RP-G28 including his thoughts on trial design, treatment benefit
assessment and probability of success.
Ritter Pharmaceuticals expects to achieve major
milestones in 2019, including the completion and data readout of
its first pivotal phase 3 trial in lactose intolerance which is
expected in the second half of 2019. In December 2018, the Company
announced that it had reached the halfway-mark for enrollment in
this trial. The 525-subject multicenter, randomized, double-blind,
placebo-controlled, parallel-group study continues to enroll
on-time. Persons interested in participating in the Liberatus study
may receive more information by visiting www.clinicaltrials.gov
(NCT03597516) or by visiting
www.liberatusstudy.com/clinical-research.
About Ritter Pharmaceuticals
Ritter Pharmaceuticals, Inc.
(www.ritterpharma.com, @RitterPharma) develops innovative
therapeutic products that modulate the gut microbiome to treat
gastrointestinal diseases. The Company’s lead product candidate,
RP-G28, has the potential to become the first FDA-approved
treatment for lactose intolerance, a condition that affects
millions worldwide. RP-G28 is in Phase 3 clinical development with
its first Phase 3 clinical trial, known as “Liberatus,” currently
underway. The Company is further exploring the therapeutic
potential that gut microbiome changes may have on
treating/preventing a variety of diseases including:
gastrointestinal diseases, cancer, metabolic, and liver
disease.
About Dr. William Chey
Dr. Chey is Nostrant Collegiate Professor of
Gastroenterology & Nutrition Sciences, Director of the GI
Physiology Laboratory, and Co-Director of the Michigan Bowel
Control Program at Michigan Medicine. He also serves as a member of
the Board of Trustees of the American College of Gastroenterology,
the Board of Directors of the Rome Foundation and a member of the
Advisory Board of the International Foundation of Functional GI
Disorders. Dr. Chey has authored more than 300 manuscripts, reviews
and book chapters, and he was the Co-Editor-in-Chief of the
American Journal of Gastroenterology from 2010 to 2015. He has been
elected to “Best Doctors” since 2001 and “America’s Top Doctors”
since 2009. Dr. Chey has been inducted into the Clinical Excellence
Society of the Department of Medicine, received the Dean’s
Outstanding Clinician Award, was inducted into the League of
Research Excellence at the University of Michigan and has received
the Distinguished Clinician Award from the American
Gastroenterological Association. Dr. Chey received his B.A. from
the University of Pennsylvania and medical degree and training in
internal medicine at the Emory University School of Medicine,
completing his fellowship in gastroenterology at the University of
Michigan.
Forward-Looking Statements
This press release may contain forward-looking
statements within the meaning of the Private Securities Litigation
Reform Act of 1995 that express the current beliefs and
expectations of Ritter Pharmaceuticals’ management. Any statements
contained herein that do not describe historical facts are
forward-looking statements. Forward-looking statements are subject
to risks and uncertainties that could cause actual results,
performance and achievements to differ materially from those
discussed in such forward-looking statements. Some of the factors
that could affect our actual results are included in the periodic
reports on Form 10-K and Form 10-Q that we file with the Securities
and Exchange Commission. Ritter cautions readers not to place undue
reliance on any forward-looking statements, which speak only as of
the date they were made. The Company undertakes no obligation to
update or revise forward-looking statements, except as otherwise
required by law, whether as a result of new information, future
events or otherwise.
ContactsInvestor Contact:John Beck 310-203-1000
john@ritterpharma.com
Media Contact:Jules Abraham
CoreIR917-885-7378julesa@coreir.com
Ritter Pharmaceuticals (NASDAQ:RTTR)
Historical Stock Chart
From Mar 2024 to Apr 2024
Ritter Pharmaceuticals (NASDAQ:RTTR)
Historical Stock Chart
From Apr 2023 to Apr 2024